CN113735792A - 氯苯唑酸葡胺及其中间体的制备方法 - Google Patents
氯苯唑酸葡胺及其中间体的制备方法 Download PDFInfo
- Publication number
- CN113735792A CN113735792A CN202111105214.1A CN202111105214A CN113735792A CN 113735792 A CN113735792 A CN 113735792A CN 202111105214 A CN202111105214 A CN 202111105214A CN 113735792 A CN113735792 A CN 113735792A
- Authority
- CN
- China
- Prior art keywords
- gas
- compound
- preparation
- temperature
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 39
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 title description 2
- 229960003291 chlorphenamine Drugs 0.000 title description 2
- 238000006482 condensation reaction Methods 0.000 claims abstract description 38
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 36
- 150000001875 compounds Chemical class 0.000 claims abstract description 32
- 239000003513 alkali Substances 0.000 claims abstract description 29
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims abstract description 27
- 229960003194 meglumine Drugs 0.000 claims abstract description 27
- IKCLCGXPQILATA-UHFFFAOYSA-N 2-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229940125782 compound 2 Drugs 0.000 claims abstract description 23
- 239000003960 organic solvent Substances 0.000 claims abstract description 21
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229940125898 compound 5 Drugs 0.000 claims abstract description 18
- 229940125904 compound 1 Drugs 0.000 claims abstract description 13
- 229940126214 compound 3 Drugs 0.000 claims abstract description 10
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 10
- 239000003054 catalyst Substances 0.000 claims abstract description 8
- 239000007789 gas Substances 0.000 claims description 134
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 48
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 46
- 239000002904 solvent Substances 0.000 claims description 34
- 238000006243 chemical reaction Methods 0.000 claims description 33
- 238000003756 stirring Methods 0.000 claims description 29
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 24
- 238000001914 filtration Methods 0.000 claims description 23
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 21
- 238000004537 pulping Methods 0.000 claims description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 238000001816 cooling Methods 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 10
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 claims description 10
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 230000001681 protective effect Effects 0.000 claims description 8
- LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 6
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 5
- 150000007530 organic bases Chemical class 0.000 claims description 5
- -1 in the step 4 Substances 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 229910052786 argon Inorganic materials 0.000 claims description 4
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 claims description 4
- 150000007524 organic acids Chemical group 0.000 claims description 4
- NZYOAGBNMCVQIV-UHFFFAOYSA-N sodium;chloro-(4-methylphenyl)sulfonylazanide;trihydrate Chemical compound O.O.O.[Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 NZYOAGBNMCVQIV-UHFFFAOYSA-N 0.000 claims description 4
- 150000007522 mineralic acids Chemical class 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 239000007810 chemical reaction solvent Substances 0.000 claims description 2
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 claims description 2
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 10
- 230000035484 reaction time Effects 0.000 claims 4
- 125000001033 ether group Chemical group 0.000 claims 3
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 7
- 238000009776 industrial production Methods 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 3
- 230000007613 environmental effect Effects 0.000 abstract 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 17
- 239000000047 product Substances 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 9
- 238000001035 drying Methods 0.000 description 7
- 238000010009 beating Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 238000002386 leaching Methods 0.000 description 4
- DQJDBUPLRMRBAB-WZTVWXICSA-N tafamidis meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O1C2=CC(C(=O)O)=CC=C2N=C1C1=CC(Cl)=CC(Cl)=C1 DQJDBUPLRMRBAB-WZTVWXICSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- TXEIIPDJKFWEEC-UHFFFAOYSA-N tafamidis Chemical compound O1C2=CC(C(=O)O)=CC=C2N=C1C1=CC(Cl)=CC(Cl)=C1 TXEIIPDJKFWEEC-UHFFFAOYSA-N 0.000 description 3
- 229960001353 tafamidis Drugs 0.000 description 3
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 2
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229940121767 Transthyretin stabilizer Drugs 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 201000007905 transthyretin amyloidosis Diseases 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- SDOFMBGMRVAJNF-SLPGGIOYSA-N (2r,3r,4r,5s)-6-aminohexane-1,2,3,4,5-pentol Chemical compound NC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SDOFMBGMRVAJNF-SLPGGIOYSA-N 0.000 description 1
- JONFYSWOLCTYFK-UHFFFAOYSA-N 2-(2,3-dichloroanilino)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(Cl)=C1Cl JONFYSWOLCTYFK-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- CWFOCCVIPCEQCK-UHFFFAOYSA-N chlorfenapyr Chemical compound BrC1=C(C(F)(F)F)N(COCC)C(C=2C=CC(Cl)=CC=2)=C1C#N CWFOCCVIPCEQCK-UHFFFAOYSA-N 0.000 description 1
- 229950009130 clofenamic acid Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940081715 tafamidis meglumine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
Abstract
Description
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111105214.1A CN113735792A (zh) | 2021-09-22 | 2021-09-22 | 氯苯唑酸葡胺及其中间体的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111105214.1A CN113735792A (zh) | 2021-09-22 | 2021-09-22 | 氯苯唑酸葡胺及其中间体的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113735792A true CN113735792A (zh) | 2021-12-03 |
Family
ID=78740154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111105214.1A Pending CN113735792A (zh) | 2021-09-22 | 2021-09-22 | 氯苯唑酸葡胺及其中间体的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113735792A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114716314A (zh) * | 2022-04-01 | 2022-07-08 | 恒翼生物医药(上海)股份有限公司 | 一种含苯环类化合物的盐、其制备方法及应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1835926A (zh) * | 2003-06-17 | 2006-09-20 | 詹森药业有限公司 | 非肽类取代螺苯并氮杂䓬衍生物的制备方法 |
WO2020207753A1 (en) * | 2019-04-11 | 2020-10-15 | Inke, S.A. | Process for preparing 1-deoxy-1-methylamino-d-glucitol 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate |
WO2021019448A1 (en) * | 2019-08-01 | 2021-02-04 | Honour (R&D) | Process for the preparation of transthyretin dissociation inhibitor |
WO2021152623A1 (en) * | 2020-01-27 | 2021-08-05 | Dr. Reddy’S Laboratories Limited | Improved processes for the preparation of tafamidis and its meglumine salt |
CN113372290A (zh) * | 2021-05-21 | 2021-09-10 | 遵义医科大学 | 一种药物Tafamidis的合成方法 |
-
2021
- 2021-09-22 CN CN202111105214.1A patent/CN113735792A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1835926A (zh) * | 2003-06-17 | 2006-09-20 | 詹森药业有限公司 | 非肽类取代螺苯并氮杂䓬衍生物的制备方法 |
WO2020207753A1 (en) * | 2019-04-11 | 2020-10-15 | Inke, S.A. | Process for preparing 1-deoxy-1-methylamino-d-glucitol 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate |
WO2021019448A1 (en) * | 2019-08-01 | 2021-02-04 | Honour (R&D) | Process for the preparation of transthyretin dissociation inhibitor |
WO2021152623A1 (en) * | 2020-01-27 | 2021-08-05 | Dr. Reddy’S Laboratories Limited | Improved processes for the preparation of tafamidis and its meglumine salt |
CN113372290A (zh) * | 2021-05-21 | 2021-09-10 | 遵义医科大学 | 一种药物Tafamidis的合成方法 |
Non-Patent Citations (1)
Title |
---|
GARY M. COPPOLA等: "Perhydroquinolylbenzamides as Novel Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1", 《J. MED. CHEM.》, vol. 48, no. 21, pages 6696 - 6712, XP002376625, DOI: 10.1021/jm058228q * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114716314A (zh) * | 2022-04-01 | 2022-07-08 | 恒翼生物医药(上海)股份有限公司 | 一种含苯环类化合物的盐、其制备方法及应用 |
CN114716314B (zh) * | 2022-04-01 | 2024-01-02 | 恒翼生物医药(上海)股份有限公司 | 一种含苯环类化合物的盐、其制备方法及应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106256824B (zh) | 一种高纯度德拉沙星葡甲胺盐的制备方法 | |
CN110563780B (zh) | 一种三氯蔗糖氯化液的后处理方法及其在三氯蔗糖制备中的应用 | |
WO2023071293A1 (zh) | 一种莫匹拉韦的制备方法 | |
CN110590635A (zh) | 左乙拉西坦及其中间体的制备方法 | |
CN113121416A (zh) | 一种雷芬那辛的制备方法 | |
CN109180436A (zh) | 一种间苯三酚的合成方法 | |
CN113735792A (zh) | 氯苯唑酸葡胺及其中间体的制备方法 | |
CN105859686B (zh) | 一种达比加群酯游离碱的精制方法 | |
CN106279207A (zh) | 一种头孢地尼的合成方法 | |
CN110551052A (zh) | (r)-4-羟基-2-氧代-1-吡咯烷乙酸酯的制备方法 | |
US20060135784A1 (en) | Process for producing 3-amino-2-hydroxypropionic acid derivatives | |
CN105085524A (zh) | 一种制备高纯度盐酸缬更昔洛韦的方法 | |
TW202200546A (zh) | 芳香醚類化合物的製備方法 | |
CN112939941A (zh) | 一种兰索拉唑的制备方法 | |
CN110655535A (zh) | 一种替诺福韦的纯化方法 | |
JP4397990B2 (ja) | 3−アルキルフラバノノール誘導体の精製法 | |
CN116396330B (zh) | 一种环丙基取代的2h-苯并吡喃衍生物的制备方法 | |
CN115448912B (zh) | 泊沙康唑中间体的制备方法 | |
CN115716817B (zh) | 6,8-环三硫辛酸的制备方法 | |
EP3722285B1 (en) | Process for preparing mirabegron enacarbil | |
CN108929236A (zh) | 盐酸托莫西汀的制备 | |
CN107709313A (zh) | 一种制备三苯甲基坎地沙坦的方法 | |
CN116120395A (zh) | 一种奈玛特韦中间体的制备方法 | |
JPH0468301B2 (zh) | ||
CN117327021A (zh) | 一种去除六氢哒嗪合成中粘稠物杂质的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 201306 floor 3 and 4, Building 29, No. 356, ZHENGBO Road, Lingang xinpian District, China (Shanghai) pilot Free Trade Zone, Fengxian District, Shanghai Applicant after: Shanghai xinlitai Pharmaceutical Co.,Ltd. Applicant after: Shanghai Yunshengyan neoplasm Technology Co.,Ltd. Address before: 201306 floor 3 and 4, Building 29, No. 356, ZHENGBO Road, Lingang xinpian District, China (Shanghai) pilot Free Trade Zone, Fengxian District, Shanghai Applicant before: Shanghai xinlitai Pharmaceutical Co.,Ltd. Applicant before: SHANGHAI BOCIMED PHARMACEUTICAL Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230519 Address after: 201306 floor 3 and 4, Building 29, No. 356, ZHENGBO Road, Lingang xinpian District, China (Shanghai) pilot Free Trade Zone, Fengxian District, Shanghai Applicant after: Shanghai xinlitai Pharmaceutical Co.,Ltd. Address before: 201306 floor 3 and 4, Building 29, No. 356, ZHENGBO Road, Lingang xinpian District, China (Shanghai) pilot Free Trade Zone, Fengxian District, Shanghai Applicant before: Shanghai xinlitai Pharmaceutical Co.,Ltd. Applicant before: Shanghai Yunshengyan neoplasm Technology Co.,Ltd. |